A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

Trial Profile

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors MedImmune
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 08 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top